{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:15:49Z","timestamp":1791605749728,"version":"4.3.4"},"reference-count":33,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100014382","name":"IPSEN","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Prognosis of anaplastic thyroid cancer (ATC) remains poor. In the absence of immediately actionable molecular alterations, guidelines recommend multimodal therapy including radiotherapy and cytotoxic chemotherapy, but optimal regimens are not established. Many centers in Germany have adopted carboplatin\/paclitaxel (CP), with or without radiotherapy, as a preferred first-line approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to compare the outcome of patients treated first-line with CP \u00b1 radiotherapy vs other cytotoxic chemotherapy regimens in ATC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective multicenter registry study in Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting and patients<\/jats:title>\n                    <jats:p>158 adults with histologically confirmed ATC treated with first-line cytotoxic chemotherapy at 7 German tertiary centers (2000-2024).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures<\/jats:title>\n                    <jats:p>Progression-free survival (PFS) and overall survival (OS) were compared with Kaplan\u2013Meier and log-rank tests; a Cox proportional hazard model was used to identify risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>97 patients received first-line CP, and 61 received other chemotherapy. PFS (102 vs 89 days; log-rank P = .23) and OS (278 vs 295 days; P = .50) did not differ between CP and other regimens. Complete response occurred in 13% with CP and 8% with other chemotherapy (P = .46). In multivariable analyses, age \u226565 years, lymph node metastasis, and distant metastasis were associated with higher mortality risk. Surgery was associated with a lower mortality risk. CP was not associated with improved OS. The outcome of second-line treatment was not different for chemotherapy vs kinase inhibition \u00b1 immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this registry study, CP showed no survival benefit in ATC; outcomes depended on disease burden and resectability, underscoring the need for rapid molecular diagnostics. Chemotherapy may serve as a bridging strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag177","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T11:24:18Z","timestamp":1776684258000},"page":"2861-2870","source":"Crossref","is-referenced-by-count":1,"title":["Outcome of first-line chemotherapy for anaplastic thyroid cancer\u2014a multicenter registry analysis"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2278-9044","authenticated-orcid":false,"given":"Katharina Elisabeth","family":"Graf","sequence":"first","affiliation":[{"name":"Department of Internal Medicine IV, University Hospital Munich, LMU Munich , 80336 Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3862-4639","authenticated-orcid":false,"given":"Pia","family":"Adam","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, University Hospital Munich, LMU Munich , 80336 Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9399-1912","authenticated-orcid":false,"given":"Felix","family":"Megerle","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital W\u00fcrzburg, University of W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9441-3046","authenticated-orcid":false,"given":"Yara Maria","family":"Machlah","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, Endocrine Tumor Center at the West German Cancer Center, University Hospital Essen, University of Duisburg-Essen , 45147 Essen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7377-0220","authenticated-orcid":false,"given":"Dominik","family":"Soll","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Charit\u00e9, Universit\u00e4tsmedizin Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, European Reference Network on Rare Endocrine Diseases (ENDO-ERN) , 10117 Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2307-1728","authenticated-orcid":false,"given":"Christina M","family":"Berr","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, 1st Medical Clinic, University Hospital Augsburg , 86156 Augsburg ,","place":["Germany"]},{"name":"Augsburg Site, Bavarian Cancer Research Center , 86156 Augsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilka","family":"Budde","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital W\u00fcrzburg, University of W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2989-5883","authenticated-orcid":false,"given":"Christian H","family":"Pfob","sequence":"additional","affiliation":[{"name":"Augsburg Site, Bavarian Cancer Research Center , 86156 Augsburg, Germany"},{"name":"Nuclear Medicine, Faculty of Medicine, University of Augsburg , 86156 Augsburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"K\u00e4smann","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital of Munich, LMU Munich , 81377 Munich ,","place":["Germany"]},{"name":"Munich Site, Bavarian Cancer Research Center , 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1466-5287","authenticated-orcid":false,"given":"Carmina Teresa","family":"Fu\u00df","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital W\u00fcrzburg, University of W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]},{"name":"Comprehensive Cancer Center Mainfranken , 97080 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"K\u00fcppers","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital W\u00fcrzburg, University of W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8709-7252","authenticated-orcid":false,"given":"Stefanie","family":"Corradini","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Hospital of Munich, LMU Munich , 81377 Munich ,","place":["Germany"]},{"name":"Munich Site, Bavarian Cancer Research Center , 81377 Munich, Germany"},{"name":"Comprehensive Cancer Center Munich, University Hospital of Munich, LMU Munich, 80336 Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-3155","authenticated-orcid":false,"given":"Knut","family":"Mai","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Charit\u00e9, Universit\u00e4tsmedizin Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health, European Reference Network on Rare Endocrine Diseases (ENDO-ERN) , 10117 Berlin ,","place":["Germany"]},{"name":"Department of Human Nutrition, German Institute of Human Nutrition Potsdam-Rehbru\u0308cke , 14558 Nuthetal ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schott","sequence":"additional","affiliation":[{"name":"Division for Specific Endocrinology, Medical Faculty, University of D\u00fcsseldorf , 40215 D\u00fcsseldorf ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Sandner","sequence":"additional","affiliation":[{"name":"Department of Medicine III, Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center , 04103 Leipzig ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"F\u00fchrer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, Endocrine Tumor Center at the West German Cancer Center, University Hospital Essen, University of Duisburg-Essen , 45147 Essen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Spitzweg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, University Hospital Munich, LMU Munich , 80336 Munich ,","place":["Germany"]},{"name":"Munich Site, Bavarian Cancer Research Center , 81377 Munich, Germany"},{"name":"Comprehensive Cancer Center Munich, University Hospital of Munich, LMU Munich, 80336 Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-6398","authenticated-orcid":false,"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital W\u00fcrzburg, University of W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]},{"name":"Comprehensive Cancer Center Mainfranken , 97080 W\u00fcrzburg ,","place":["Germany"]},{"name":"Bavarian Cancer Research Center , 97080 W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2904-4341","authenticated-orcid":false,"given":"Tim","family":"Brandenburg","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, Endocrine Tumor Center at the West German Cancer Center, University Hospital Essen, University of Duisburg-Essen , 45147 Essen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria Florentine","family":"Koehler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, University Hospital Munich, LMU Munich , 80336 Munich ,","place":["Germany"]},{"name":"Department of Medicine I, University Hospital Frankfurt, Goethe-Universit\u00e4t Frankfurt , 60596 Frankfurt ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7628-3161","authenticated-orcid":false,"given":"Matthias","family":"Kroiss","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, University Hospital Munich, LMU Munich , 80336 Munich ,","place":["Germany"]},{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital W\u00fcrzburg, University of W\u00fcrzburg , 97080 W\u00fcrzburg ,","place":["Germany"]},{"name":"Munich Site, Bavarian Cancer Research Center , 81377 Munich, Germany"},{"name":"Comprehensive Cancer Center Munich, University Hospital of Munich, LMU Munich, 80336 Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"6","key":"2026091519582233500_dgag177-B1","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clon.2010.03.013","article-title":"Anaplastic thyroid carcinoma: pathogenesis and emerging therapies","volume":"22","author":"Smallridge","year":"2010","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"4","key":"2026091519582233500_dgag177-B2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S2213-8587(21)00027-9","article-title":"Thyroid cancer incidence trends by histology in 25 countries: a population-based study","volume":"9","author":"Miranda-Filho","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2026091519582233500_dgag177-B3","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1530\/EJE-16-0574","article-title":"Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany","volume":"175","author":"Wendler","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2026091519582233500_dgag177-B4","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","article-title":"Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019","volume":"6","author":"Maniakas","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026091519582233500_dgag177-B5","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/542358","article-title":"Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment","volume":"2011","author":"Nagaiah","year":"2011","journal-title":"J Oncol"},{"key":"2026091519582233500_dgag177-B6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.canep.2018.01.011","article-title":"Anaplastic thyroid carcinoma in Denmark 1996-2012: a national prospective study of 219 patients","volume":"53","author":"Hvilsom","year":"2018","journal-title":"Cancer Epidemiol"},{"key":"2026091519582233500_dgag177-B7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.humpath.2018.07.027","article-title":"Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical, and molecular single-institution study","volume":"82","author":"Deeken-Draisey","year":"2018","journal-title":"Hum Pathol"},{"issue":"4","key":"2026091519582233500_dgag177-B8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1245\/ASO.2006.05.042","article-title":"Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches","volume":"13","author":"Are","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"2026091519582233500_dgag177-B9","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3390\/cancers14041061","article-title":"Anaplastic thyroid carcinoma: an update","volume":"14","author":"Jannin","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2026091519582233500_dgag177-B10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/thy.2020.0944","article-title":"2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid"},{"key":"2026091519582233500_dgag177-B11","author":"Guideline Program Oncology (German Cancer Society GCA, Association of the Scientific Medical Societies in Germany)"},{"issue":"1","key":"2026091519582233500_dgag177-B12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026091519582233500_dgag177-B13","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"},{"issue":"2","key":"2026091519582233500_dgag177-B14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","article-title":"Genomic alterations in thyroid cancer: biological and clinical insights","volume":"20","author":"Landa","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"2026091519582233500_dgag177-B15","first-page":"63","article-title":"Protokoll zur multimodalen Therapie des anaplastischen Schilddr\u00fcsenkarzinoms","volume":"39","author":"Tiedje","year":"2015","journal-title":"Endokrinol Inform"},{"issue":"10","key":"2026091519582233500_dgag177-B16","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1089\/thy.2023.0164","article-title":"Factors associated with survival in anaplastic thyroid carcinoma: a multicenter study from the ENDOCAN-TUTHYREF network","volume":"33","author":"Jannin","year":"2023","journal-title":"Thyroid"},{"issue":"9","key":"2026091519582233500_dgag177-B17","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/1097-0142(19851101)56:9<2155::AID-CNCR2820560903>3.0.CO;2-E","article-title":"A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma","volume":"56","author":"Shimaoka","year":"1985","journal-title":"Cancer"},{"issue":"1","key":"2026091519582233500_dgag177-B18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1089\/thy.2009.0115","article-title":"Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma","volume":"20","author":"Higashiyama","year":"2010","journal-title":"Thyroid"},{"issue":"8","key":"2026091519582233500_dgag177-B19","doi-asserted-by":"crossref","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","article-title":"Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Haddad","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"2026091519582233500_dgag177-B20","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1089\/thy.2016.0072","article-title":"The safety and efficacy of Weekly Paclitaxel Administration for Anaplastic Thyroid Cancer Patients: a nationwide prospective study","volume":"26","author":"Onoda","year":"2016","journal-title":"Thyroid"},{"key":"2026091519582233500_dgag177-B21","doi-asserted-by":"crossref","first-page":"1385747","DOI":"10.3389\/fendo.2024.1385747","article-title":"Emerging chemotherapy-based treatments in anaplastic thyroid cancer: an updated analysis of prospective studies","volume":"15","author":"Wang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026091519582233500_dgag177-B22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00595-013-0751-x","article-title":"Chemotherapy for anaplastic thyroid cancer using docetaxel and cisplatin: report of eight cases","volume":"45","author":"Seto","year":"2015","journal-title":"Surg Today"},{"issue":"2","key":"2026091519582233500_dgag177-B23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1089\/thy.2013.0078","article-title":"Randomized safety and efficacy study of fosbretabulin with paclitaxel\/carboplatin against anaplastic thyroid carcinoma","volume":"24","author":"Sosa","year":"2014","journal-title":"Thyroid"},{"issue":"7","key":"2026091519582233500_dgag177-B24","first-page":"1496","article-title":"An overview on prevalence and detection approaches of BRAF V600E mutation in anaplastic thyroid carcinoma: a systematic review and meta-analysis","volume":"53","author":"Behnagh","year":"2024","journal-title":"Iran J Public Health"},{"issue":"26","key":"2026091519582233500_dgag177-B25","doi-asserted-by":"crossref","first-page":"42613","DOI":"10.18632\/oncotarget.17300","article-title":"NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma","volume":"8","author":"Tiedje","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2026091519582233500_dgag177-B26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40425-018-0378-y","article-title":"Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma","volume":"6","author":"Iyer","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2026091519582233500_dgag177-B27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13044-023-00147-7","article-title":"Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer","volume":"16","author":"Lang","year":"2023","journal-title":"Thyroid Res"},{"issue":"4","key":"2026091519582233500_dgag177-B28","first-page":"903","article-title":"Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer","volume":"7","author":"Jing","year":"2017","journal-title":"Am J Cancer Res"},{"issue":"3","key":"2026091519582233500_dgag177-B29","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1089\/thy.2023.0573","article-title":"Checkpoint inhibition in addition to dabrafenib\/trametinib for BRAF(V600E)-mutated anaplastic thyroid carcinoma","volume":"34","author":"Hamidi","year":"2024","journal-title":"Thyroid"},{"issue":"2","key":"2026091519582233500_dgag177-B30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(22)00763-X","article-title":"Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG\/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial","volume":"24","author":"Sherman","year":"2023","journal-title":"Lancet Oncol"},{"issue":"11","key":"2026091519582233500_dgag177-B31","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1089\/thy.2019.0086","article-title":"A phase 2 study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer","volume":"29","author":"Chintakuntlawar","year":"2019","journal-title":"Thyroid"},{"issue":"1","key":"2026091519582233500_dgag177-B32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11154-023-09833-1","article-title":"Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease","volume":"25","author":"Califano","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"key":"2026091519582233500_dgag177-B33","doi-asserted-by":"crossref","first-page":"1365055","DOI":"10.3389\/fonc.2024.1365055","article-title":"Research progress of immunotherapy against anaplastic thyroid cancer","volume":"14","author":"Chen","year":"2024","journal-title":"Front Oncol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag177\/68173279\/dgag177.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/10\/2861\/68173279\/dgag177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/10\/2861\/68173279\/dgag177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:58:33Z","timestamp":1789516713000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/10\/2861\/8659430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,4,21]]},"published-print":{"date-parts":[[2026,9,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag177","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,4,21]]}}}